combine celecoxib with chemotherapies for head and neck cancer."
Trask's research team included Jonathan Bock, M.D., a UI resident in otolaryngology and lead author of the two studies published in recent issues of the journals Molecular Carcinogenesis and Cancer Research. Prabhat Goswami, Ph.D., UI assistant professor, and Frederick Domann, Ph.D., UI professor, both faculty in radiation oncology and in the Free Radical and Radiation Biology Graduate Program, also were part of the UI team. Trask, Goswami and Domann all are members of the Holden Comprehensive Cancer Center at the UI.
Goswami and Domann added that when radiation is used to treat head and neck cancers after surgery, the cells most resistant to radiation therapy are in the S phase. Thus celecoxib's selective killing of cells in S phase suggests this class of drug may target the radio-resistant cells, and use of the drug together with radiation might provide better tumor control than radiation alone.
Because inflammation is thought to play a role in the development of certain cancers, numerous studies have investigated the role of nonsteroidal anti-inflammatory drugs in cancer prevention. However, few studies have systematically evaluated the relative anticancer activity of different NSAIDS.
In one study, published in the April 5 online issue of Molecular Carcinogenesis, the UI scientists tested 10 commercially available NSAIDs against head and neck cancer cells. They found that celecoxib and sulindac sulfide, (sold as Clinoril sulfide) are particularly effective at slowing cancer cell proliferation and at killing cancer cells. Of these two, celecoxib is by far the most potent, killing up to 60 percent of head and neck cancer cells under the study conditions. None of the other 10 NSAIDs in the study, including aspirin, naproxen (Aleve) or rofecoxib (Vioxx), showed effective anticancer activity.
The experiments also indicated that celecoPage: 1 2 3 Related medicine news :1
. Tamiflu Shortage Can Be Better Handled By Combining It With Probenecid 2
. Combining Therapies can Improve Survival for Early-stage Breast Cancer Patients3
. The Effectiveness Of NSAIDs Evaluated4
. NSAIDs In First trimester Linked To Congenital Anomalies In Babies5
. Study Explains How NSAIDs Halt Cancer Growth6
. Aspirin Or NSAIDs Will not Prevent Colorectal Cancer7
. Acupuncture May Help Chemotherapy Side Effects8
. Chemotherapy Pill Has Fewer Side Effects Than IV
. Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy"10
. Therapy Boosts Chemotherapy Effects11
. Chemotherapy Effective for Bladder Cancer